MedTrace Logo

Study of the CD40 Agonistic Monoclonal Antibody APX005M

NCT02482168 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-12-20

No results posted yet for this study

Summary

This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.

Conditions

Interventions

DRUG

APX005M

APX005M is a CD40 agonistic monoclonal antibody

Sponsors & Collaborators

  • Apexigen America, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Apexigen America, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-06-13
Completion
2018-06-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482168 on ClinicalTrials.gov